Table 1.
Characteristics of in Japanese subjects with prostate cancer (n = 234)
| Degarelix | Goserelin | |
|---|---|---|
| FAS, n | 117 | 117 |
| Age, years; mean ± SD | 75.5 ± 6.1 | 75.9 ± 5.9 |
| Classification, n (%) | ||
| <75 | 41 (35.0) | 42 (35.9) |
| ≥75 | 76 (65.0) | 75 (64.1) |
| Height, cm; mean ± SD | 163.48 ± 6.27 | 163.13 ± 5.64 |
| Body weight, kg; mean ± SD | 62.83 ± 10.05 | 62.93 ± 8.18 |
| ECOG PS, n (%) | ||
| 0 | 110 (94.0) | 114 (97.4) |
| 1 | 6 (5.1) | 3 (2.6) |
| 2 | 1 (0.9) | 0 (0.0) |
| 3 | 0 (0.0) | 0 (0.0) |
| 4 | 0 (0.0) | 0 (0.0) |
| Pretreatment, n (%) | 9 (7.7%) | 12 (10.3) |
| Total prostatectomy | 2 (1.7) | 1 (0.9) |
| Radiation | 3 (2.6) | 3 (2.6) |
| Neoadjuvant/adjuvant therapy | 1 (0.9) | 0 (0.0) |
| Watchful waiting | 5 (4.3) | 9 (7.7) |
| Cancer stage, n (%) | ||
| Localized | 62 (53.0) | 62 (53.0) |
| Locally advanced | 30 (25.6) | 33 (28.2) |
| Metastasized | 23 (19.7) | 21 (17.9) |
| Unclassifiable | 2 (1.7) | 1 (0.9) |
| Serum testosterone level, ng/mL; mean ± SD | 4.98 ± 1.41 | 4.94 ± 1.59 |
| Classification, n (%) | ||
| <3.5 ng/mL | 16 (13.7) | 20 (17.1) |
| ≥3.5 to <5 ng/mL | 50 (42.7) | 45 (38.5) |
| ≥5 ng/mL | 51 (43.6) | 52 (44.4) |
| Serum PSA level, ng/mL; mean ± SD | 66.04 ± 140.33 | 61.08 ± 121.28 |
| Classification, n (%) | ||
| <10 ng/mL | 42 (35.9) | 43 (36.8) |
| ≥10 ng/mL to <20 ng/mL | 26 (22.2) | 23 (19.7) |
| ≥20 ng/mL to <50 ng/mL | 20 (17.1) | 21 (17.9) |
| ≥50 ng/mL | 29 (24.8) | 30 (25.6) |
FAS, full analysis set; PS, performance status; PSA, prostate‐specific antigen.